Page 82 - Read Online
P. 82

Moore et al. J Transl Genet Genom 2021;5:200-217  https://dx.doi.org/10.20517/jtgg.2021.08  Page 13

               Business and Knowledge of the Government of Catalonia (2017SGR1085) who had no role in the data
               collection, analysis or interpretation of the results; the NIH (contract NO1-CO-12400); the Compagnia di
               San Paolo-Programma Oncologia; the Federal Office for Radiation Protection grants StSch4261 and
               StSch4420, the José Carreras Leukemia Foundation grant DJCLS-R12/23, the German Federal Ministry for
               Education and Research (BMBF-01-EO-1303); the Health Research Board, Ireland and Cancer Research
               Ireland; Czech Republic supported by MH CZ - DRO (MMCI, 00209805) and MEYS - NPSI - LO1413;
               Fondation de France and Association de Recherche Contre le Cancer.
               GEC/Mayo GWAS - National Institutes of Health (CA118444, CA148690, CA92153). Intramural Research
               Program of the NIH, National Cancer Institute. Veterans Affairs Research Service. Data collection for Duke
               University was supported by a Leukemia & Lymphoma Society Career Development Award, the Bernstein
               Family Fund for Leukemia and Lymphoma Research, and the National Institutes of Health (K08CA134919),
               National Center for Advancing Translational Science (UL1 TR000135).
               HPFS (Walter C. Willet) - The HPFS was supported in part by National Institutes of Health grants U01
               CA167552, R01 CA149445, and R01 CA098122. We would like to thank the participants and staff of the
               Health Professionals Follow-up Study for their valuable contributions as well as the following state cancer
               registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI,
               NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full
               responsibility for analyses and interpretation of these data. The study protocol was approved by the
               institutional review boards of the Brigham and Women’s Hospital and Harvard T.H. Chan School of Public
               Health, and those of participating registries as required.
               Iowa-Mayo SPORE - NCI Specialized Programs of Research Excellence (SPORE) in Human Cancer (P50
               CA97274); National Cancer Institute (P30 CA086862, P30 CA15083); Henry J. Predolin Foundation.
               Italian GxE - Italian Association for Cancer Research (AIRC, Investigator Grant 11855) (PC); Fondazione
               Banco di Sardegna 2010-2012, and Regione Autonoma della Sardegna (LR7 CRP-59812/2012) (MGE).
               Mayo Clinic Case-Control - National Institutes of Health (R01 CA92153 and CA200703); National Cancer
               Institute (P30 CA015083).
               MCCS - The Melbourne Collaborative Cohort Study recruitment was funded by VicHealth and Cancer
               Council Victoria. The MCCS was further supported by Australian NHMRC grants 209057, 396414 and
               1074383 and by infrastructure provided by Cancer Council Victoria. Cases and their vital status were
               ascertained through the Victorian Cancer Registry (VCR) and the Australian Institute of Health and
               Welfare (AIHW), including the National Death Index and the Australian Cancer Database.
               MSKCC - Geoffrey Beene Cancer Research Grant, Lymphoma Foundation (LF5541); Barbara K. Lipman
               Lymphoma Research Fund (74419); Robert and Kate Niehaus Clinical Cancer Genetics Research Initiative
               (57470); U01 HG007033; ENCODE; U01 HG007033.
               NCI-SEER - Intramural Research Program of the National Cancer Institute, National Institutes of Health,
               and Public Health Service (N01-PC-65064, N01-PC-67008, N01-PC-67009, N01-PC-67010, N02-PC-71105).
               NHS (Meir J. Stampfer) - The NHS was supported in part by National Institutes of Health grants
               CA186107, CA87969, CA49449, CA149445, CA098122 and CA134958. We would like to thank the
               participants and staff of the Nurses' Health Study for their valuable contributions as well as the following
               state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME,
               MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors
               assume full responsibility for analyses and interpretation of these data.
               NSW - NSW was supported by grants from the Australian National Health and Medical Research Council
               (ID990920), the Cancer Council NSW, and the University of Sydney Faculty of Medicine.
               NYU-WHS  -  National  Cancer  Institute  (R01  CA098661,  P30  CA016087);  National  Institute  of
               Environmental Health Sciences (ES000260).
               PLCO - This research was supported by the Intramural Research Program of the National Cancer Institute
               and by contracts from the Division of Cancer Prevention, National Cancer Institute, NIH, DHHS.
   77   78   79   80   81   82   83   84   85   86   87